Table 2 Clinical characterization of the studied cohort.

Ulcerative Colitis/Crohn Disease

216(74%)/75(26%)

Sex (male/female)

111(38%)/180(62%)

Age, years, median (max–min)

50 (15–81)

Age, years, at diagnoses (median, min-max)

36 (7–73)

Disease Duration, years, (median, min-max)

9 (0–49)

Extraintestinal Manifestation (no/yes)

187(64%)/104(36%)

Hospitalization (no/yes)

139(48%)/152(52%)

Smoking (no/yes)

241(83%)/50(17%)

Hemoglobin (g/L)

(Normal range 12–18), mean (max–min)

13.76 (6.2–17.7)

White cell count ×10⁶/L

Normal range 4000–11,000, mean (max–min)

7102(1760–16740)

Platelets, ×10⁶/L

Normal range 150,000–450,000, mean (max–min)

299,620(28000–756000)

C reactive protein (mg/dL)

Normal range < 0.5, mean (max–min)

2.09(0.02-43)

Albumin (g/L)

Normal range (3.5–5.5), mean (max–min)

4.54(2.3–5.5)

Resective Surgery (no/yes)

245(84%)/46(16%)

History infection for Clostridiodes Difficile (no/yes)

262(90%)/29(10%)

Current use of steroids (no/yes)

246(85%)/45(15%)

Anti-TNFa use (no/yes)

247(85%)/44(15%)

Thiopurines/Inmunosupresor use

200(69%)/91(31%)

Naïve anti TNF (no/yes)

55(19%)/236(81%)

Montreal Ulcerative Colitis (N = 216)

Extensive colitis (E3)

120(55%)

Left colitis (E2)

56(26%)

Proctitis (E1)

38(18%)

No registered

2(1%)

Montreal Crohn´s Disease (n = 46)

Age

A1/A2/A3/No registered

6(8%)/30(40%)/38(51%)/1(1%)

Localization

Ileal (L1)

12(16%)

Colonic (L2)

38(51%)

Ileocolonic (L3)

25(33%)

Upper compromise (L4) (no/yes)

68(91%)/ 7(9%)

Behavior

B1 (inflammatory)

31(41%)

B2 (structuring)

19(25%)

B3 (penetrating)

25(33%)

Perianal Disease (no/yes)

43(57%)/32(43%)